logo
Siili Solutions Plc: Share Repurchase 25.6.2025

Siili Solutions Plc: Share Repurchase 25.6.2025

Yahoo25-06-2025
Siili Solutions Plc
Announcement 25.6.2025
Siili Solutions Plc: Share Repurchase 25.6.2025
In the Helsinki Stock Exchange
Trade date
25.6.2025
Bourse trade
Buy
Share
SIILI
Amount
600
Shares
Average price/ share
6,3400
EUR
Total cost
3 804,00
EUR
Siili Solutions Plc now holds a total of 17 749 shares
including the shares repurchased on 25.6.2025
The share buybacks are executed in compliance with Regulation
No. 596/2014 of the European Parliament and Council (MAR) Article 5
and the Commission Delegated Regulation (EU) 2016/1052.
On behalf of Siili Solutions Plc
Nordea Bank Oyj
Sami Huttunen
Ilari Isomäki
Further information:
CFO Aleksi Kankainen
Email: aleksi.kankainen@siili.com
Tel. +358 50 584 2029
www.siili.com
Attachment
SIILI 25.6.2025 Trades
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

GenSight Biologics Announces the Closing of the Company's c. €4 Million Private Placement
GenSight Biologics Announces the Closing of the Company's c. €4 Million Private Placement

Business Wire

time11 hours ago

  • Business Wire

GenSight Biologics Announces the Closing of the Company's c. €4 Million Private Placement

PARIS--(BUSINESS WIRE)--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the " Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the closing of its EUR 3,908,715.39 private placement (the ' Private Placement '). The Private Placement resulted in the issuance of 21,251,267 ordinary shares of the Company (the " Offered Shares"). The Offered Shares will be admitted to trading on Euronext Paris on July 3, 2025 (ISIN FR0013183985/SIGHT). The issuance of: The 1,850,000 pre-funded warrants (the " Offered Pre-Funded Warrants") giving the right to subscribe to 1,850,000 additional ordinary shares (the " Pre-Funded Warrant Shares"); and The 23,101,267 warrants (the " Offered Investor Warrants") giving the right to subscribe to 23,101,267 additional ordinary shares (the " Investor Warrant Shares") is expected to take place tomorrow, July 4, 2025. The Offered Investor Warrants will be admitted to trading on the Euronext Growth market in Paris (" Euronext Growth Paris") on July 7, 2025 (ISIN FR0014010IB4/SIGBS). The Offered Pre-Funded Warrants will not be admitted to trading on any venue. Part of the proceeds, EUR 0.7 million, has been used for the repayment in principal on the convertible bonds held by Heights Capital through offset against their subscription. Maxim Group, LLC acted as sole placement agent for the Private Placement in the United States, pursuant to an agreement entered into with the Company. Risk factors The Company draws the attention of the public to the risk factors relating to the Company and its business described in its 2024 Universal Registration Document, as amended by the Information Document published by the Company on July 1 st, 2025, both of which are available free of charge on the Company's website ( . About GenSight Biologics S.A. GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Disclaimer Not for release, directly or indirectly, in or into the United States of America, Canada, Australia, Japan or South Africa. This press release and the information contained herein do not contain or constitute an offer to subscribe or purchase, or the solicitation of an order to purchase or subscribe, for securities in the United States of America or in any other jurisdiction where such an offer or solicitation would be unlawful. The securities referred to herein have not been and will not be registered under the Securities Act, or under the securities laws of any state or other jurisdiction of the United States of America, and may not be offered or sold in the United States of America except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any state or any other jurisdiction of the United States. GenSight does not intend to make a public offering of the securities in the United States of America. The distribution of this press release may be subject to legal or regulatory restrictions in certain countries. Persons in possession of this press release should inform themselves of and observe any local restrictions. The information contained herein is subject to change without notice. Forward-Looking Statements This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the completion expected proceeds and anticipated use of proceeds of the Private Placement; the anticipated cash runway of the Company; and future expectations, plans and prospects of the Company. Words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'projects,' and 'future' or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed Private Placement and the terms thereof are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in the filings the Company makes with the AMF from time to time. The Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

voxeljet AG - Court confirms StaRUG Plan
voxeljet AG - Court confirms StaRUG Plan

Business Wire

time12 hours ago

  • Business Wire

voxeljet AG - Court confirms StaRUG Plan

FRIEDBERG, Germany--(BUSINESS WIRE)--voxeljet AG (the 'Company', 'voxeljet', or 'we'), a provider of high-speed, large-format 3D printers and on-demand parts services to industrial and commercial customers, today announced that main investor Anzu Special Acquisition Corp II ('Anzu') will contribute new equity capital of EUR 2.5 million as part of a plan confirmed today by the court in Munich. The plan additionally provides for a debt waiver totalling EUR 3.5 million debt owed to Anzu and extension of the debt maturity until 2031. These measures are intended to ensure the Company's long-term financing and position voxeljet for future success. CEO Rudolf Franz comments: 'We implemented the necessary process in a short period of time to minimize disruption to our operating business. With the court's confirmation of the plan, we believe this phase of the process is complete.' Franz added: 'This plan provides continuity of our operations, reinforcing our commitment to reliably serving our customers and meeting their ongoing and future needs. The plan will secure sustainable financial stability and can lead voxeljet into a successful future.' The court confirmed the plan in accordance with the German Corporate Stabilization and Restructuring Act (StaRUG) ('StaRUG Plan'). As previously communicated, the plan provides for a simplified reduction of the share capital of voxeljet AG to zero euros. The court-confirmed plan will result in the exclusion of the current shareholders of voxeljet AG without compensation. Subsequently, the company's capital will be increased excluding the subscription rights of the current shareholders. Anzu, as the only financial creditor affected by the plan, will exclusively be admitted to subscribing to the new shares. The debt waiver will be composed of EUR 500,000 to be waived in 2025 and EUR 1,500,000 in each of 2026 and 2027. Furthermore, the annual interest rate will be reduced to 3% p.a. from July 2026 onwards. No interest payments are due until after June 30, 2026. The plan also stipulates that the promissory note loans will only become due for repayment on January 2, 2031. The plan shall be implemented immediately after the plan confirmation becomes legally binding. ABOUT VOXELJET voxeljet was founded in 1999 as a spin-off from Technical University Munich (TUM) with a clear vision in mind: to establish a new manufacturing standard by developing new generative processes for the series-production of complex components using 3D printing. Voxeljet is a globally acting, leading provider of high-speed, large-format 3D printers and on-demand 3D printed parts to industrial and commercial customers. Components manufactured with the help of voxeljet technology are flying in space, make mobility more efficient and enable the production of new engineering solutions. Visit voxeljet's website and follow us on LinkedIn. ABOUT ANZU PARTNERS Anzu Partners is an investment firm that focuses on clean tech, industrial and life science technology companies with the potential to transform their industries. Anzu works with entrepreneurs to develop and commercialize technological innovations by providing capital alongside deep expertise in business development, market positioning, global connectivity, and operations. As of 2024, Anzu Partners managed assets of approximately $1 billion with a team of over fifty professionals in offices across Atlanta, Boston, San Diego, Tampa, and Washington DC. For more information, please visit

OpenPayd, Ripple forge stablecoin payments alliance
OpenPayd, Ripple forge stablecoin payments alliance

Yahoo

time17 hours ago

  • Yahoo

OpenPayd, Ripple forge stablecoin payments alliance

Financial infrastructure provider OpenPayd and Ripple have formed an alliance to enhance payment solutions for enterprise clients. The partnership will integrate OpenPayd's global fiat infrastructure, which includes real-time payment rails, multi-currency accounts, and virtual IBANs, into Ripple Payments, facilitating transactions in EUR and GBP. Ripple Payments, which employs blockchain and digital assets, aims to streamline cross-border payments and provide on/off ramps for financial institutions globally. It is also a part of the OpenPayd's stablecoin infrastructure expansion. OpenPayd will now offer direct minting and burning of Ripple USD (RLUSD), a USD-denominated stablecoin developed by Ripple. Enterprises can convert between fiat currencies and RLUSD while utilising OpenPayd's services, including account management, payments, and trading via a single API. Ripple Stablecoins SVP Jack McDonald said: 'Our collaboration with OpenPayd gives enterprises reliable access to RLUSD, combining the stability and compliance they expect with the connectivity they need. This is how we accelerate real-world adoption of stablecoins at scale.' The stablecoin RLUSD is designed to support multiple use cases such as cross-border payments, global treasury management, and access to US dollar liquidity. The partnership aims to provide enterprises with the necessary tools to conduct and manage international monetary transactions effectively. OpenPayd CEO Iana Dimitrova stated: 'By combining Ripple Payments with OpenPayd's rail agnostic and fully interoperable fiat infrastructure, we are delivering a unified platform that bridges traditional finance and blockchain. 'This partnership enables businesses to move and manage money globally, access stablecoin liquidity at scale, and simplify cross border payments, treasury flows and dollar-based operations.' Last month, OpenPayd partnered with Circle, the issuer of the USDC stablecoin, to combine traditional banking systems with blockchain technology, facilitating global business transactions. "OpenPayd, Ripple forge stablecoin payments alliance " was originally created and published by Electronic Payments International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store